(Circulation. 1999;99:2871-2875.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Improvement in Coronary Flow Reserve Determined by Positron Emission Tomography After 6 Months of Cholesterol-Lowering Therapy in Patients With Early Stages of Coronary Atherosclerosis
From the Department of Cardiology (D.B., U.G., J.L.) and the Institute of Molecular Biophysics, Radiopharmacy and Nuclear Medicine (G.N., J.H., R.W.), Heart Center Northrhine-Westphalia, Ruhr-University Bochum, Bad Oeynhausen, Germany.
Correspondence to Priv-Doz Dr Med D. Baller, Kardiologische Klinik, Herzzentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Georgstraße 11, Deutschland, 32545 Bad Oeynhausen, Germany.
Background—Early stages of coronary atherosclerosis are characterized by a mainly functional impairment of coronary vasodilator capacity under the impact of such risk factors as hypercholesterolemia. The goal of this study was to determine whether 6-month cholesterol-lowering therapy improves coronary flow reserve in patients with angina, reduced flow reserve despite minimally diseased coronary vessels or even normal angiogram, and mild to moderately elevated LDL levels on average.
Methods and Results—We noninvasively investigated 23 consecutive patients (18 men, 5 women; mean age, 56±7.6 years) with a mean LDL level of 165±34 mg/dL at baseline by PET for myocardial blood flow measurement with [13N]ammonia at rest and under dipyridamole stress (0.56 mg/kg) before and after lipid-lowering therapy with simvastatin for 6 months. Between baseline and the 6-month follow-up, total cholesterol concentration fell from 241±44 to 168±34 mg/dL, and the LDL level decreased from 165±34 to 95±26 mg/dL (P<0.001). Overall, coronary flow reserve increased from 2.2±0.6 to 2.64±0.6 (P<0.01). Maximal coronary flow increased significantly from 182±36 to 238±58 mL/minx100 g (P<0.001) at follow-up. Minimum coronary resistance declined significantly from 0.51±0.12 to 0.40±0.14 mm Hg · mL-1 · minx100 g (P<0.001). Concomitantly, a regression of anginal symptoms was observed in most patients.
Conclusions—Our results suggest that cholesterol-lowering therapy with simvastatin may improve overall coronary vasodilator capacity assessed noninvasively by PET in patients with mild to moderate hypercholesterolemia. Consequently, intensive lipid-lowering therapy is considered a vasoprotective treatment for selected patients in very early stages of coronary atherosclerosis with the potential of preventing further disease progression.
Key Words: hypercholesterolemia • coronary flow reserve • tomography • atherosclerosis • drugs
This article has been cited by other articles:
 |
|
 |
|
  J. Gronros, J. Wikstrom, U. Brandt-Eliasson, G. B. Forsberg, M. Behrendt, G. I. Hansson, and L. M. Gan Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2046 - H2053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Zoghbi, T. A. Dorfman, and A. E. Iskandrian The Effects of Medications on Myocardial Perfusion J. Am. Coll. Cardiol., August 5, 2008; 52(6): 401 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Knuuti and F M Bengel Positron emission tomography and molecular imaging Heart, March 1, 2008; 94(3): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. van der Harst, A. A. Voors, W. H. van Gilst, M. Bohm, and D. J. van Veldhuisen Statins in the treatment of chronic heart failure: Biological and clinical considerations Cardiovasc Res, August 1, 2006; 71(3): 443 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Yokoyama, Y. Inoue, T. Moritan, K. Ohtomo, and R. Nagai Impaired myocardial vasodilatation during hyperaemic stress is improved by simvastatin but not by pravastatin in patients with hypercholesterolaemia Eur. Heart J., April 2, 2004; 25(8): 671 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lethen and H. Lambertz Doppler echocardiographic assessment of coronary artery disease: a challenge becomes reality Eur J Echocardiogr, January 1, 2004; 5(1): 5 - 7. [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Balk, J. Lau, L. C. Goudas, H. S. Jordan, B. Kupelnick, L. U. Kim, and R. H. Karas Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease: A Systematic Review Ann Intern Med, October 21, 2003; 139(8): 670 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Szmitko, P. W.M. Fedak, R. D. Weisel, D. J. Stewart, M. J.B. Kutryk, and S. Verma Endothelial Progenitor Cells: New Hope for a Broken Heart Circulation, June 24, 2003; 107(24): 3093 - 3100. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wolfrum, K. S. Jensen, and J. K. Liao Endothelium-Dependent Effects of Statins Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 729 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Urbich, E. Dernbach, A. M. Zeiher, and S. Dimmeler Double-Edged Role of Statins in Angiogenesis Signaling Circ. Res., April 5, 2002; 90(6): 737 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Pearson New Tools for Coronary Risk Assessment: What Are Their Advantages and Limitations? Circulation, February 19, 2002; 105(7): 886 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fagret, C. Ghezzi, and G. Vanzetto 99mTc-N-NOET Imaging for Myocardial Perfusion: Can It Offer More Than We Already Have? J. Nucl. Med., September 1, 2001; 42(9): 1395 - 1396. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Amarenco Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction Neurology, September 1, 2001; 57(90002): S35 - 44. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Schwartz and M. G. Bourassa Evaluation of Patients With Chest Pain and Normal Coronary Angiograms Arch Intern Med, August 13, 2001; 161(15): 1825 - 1833. [Full Text] [PDF]
|
|
|
|
|
|
M. Hernandez-Pampaloni, F. Y.J. Keng, T. Kudo, J. S. Sayre, and H. R. Schelbert Abnormal Longitudinal, Base-to-Apex Myocardial Perfusion Gradient by Quantitative Blood Flow Measurements in Patients With Coronary Risk Factors Circulation, July 31, 2001; 104(5): 527 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Forrester, C. N. Bairey-Merz, and S. Kaul The aggressive low density lipoprotein lowering controversy J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1419 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Simons, R. O. Bonow, N. A. Chronos, D. J. Cohen, F. J. Giordano, H. K. Hammond, R. J. Laham, W. Li, M. Pike, F. W. Sellke, et al. Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus : An Expert Panel Summary Circulation, September 12, 2000; 102 (11): e73 - e86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Vasa, S. Fichtlscherer, K. Adler, A. Aicher, H. Martin, A. M. Zeiher, and S. Dimmeler Increase in Circulating Endothelial Progenitor Cells by Statin Therapy in Patients With Stable Coronary Artery Disease Circulation, June 19, 2001; 103(24): 2885 - 2890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Urbich, E. Dernbach, A. M. Zeiher, and S. Dimmeler Double-Edged Role of Statins in Angiogenesis Signaling Circ. Res., April 5, 2002; 90(6): 737 - 744. [Abstract] [Full Text] [PDF]
|
|